High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration
Conclusion: Intravitreal high-dose high-frequency aflibercept is an effective treatment for patients with refractory wet age-related macular degeneration. (Source: RETINA)
Source: RETINA - May 31, 2018 Category: Opthalmology Tags: Original Study Source Type: research

What Effect Does Ethnicity Have on the Response to Ranibizumab in the Treatment of Wet Age-Related Macular Degeneration?
Conclusions: Individualised ranibizumab monotherapy is more effective in preserving vision for W compared to NW patients with wet AMD.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - May 30, 2018 Category: Opthalmology Source Type: research

Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a Prospective Study in a Caucasian Population
In this study on a Caucasian population, we showed that aflibercept as a monotherapy provided both a significant visual gain and the regression of polypoidal dilations. Aflibercept use in monotherapy may contribute to reduce the hemorrhagic risk and atrophy linked to PDT.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - May 30, 2018 Category: Opthalmology Source Type: research

Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema
Conclusions: In CRVO patients, both ranibizumab and aflibercept achieved similar improvement in clinical parameters and similar reductions in aqueous VEGF, PlGF, MCP-1, and IL-6 levels.Ophthalmic Res (Source: Ophthalmic Research)
Source: Ophthalmic Research - May 30, 2018 Category: Opthalmology Source Type: research

[ASAP] Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00280 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - May 29, 2018 Category: Drugs & Pharmacology Authors: Laurence A. Hutton-Smith, Eamonn A. Gaffney, Helen M. Byrne, Antonello Caruso, Philip K. Maini, Norman A. Mazer Source Type: research

A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
Abstract Anti-vascular endothelial growth factor (VEGF) therapies lead to a major breakthrough in treatment of neovascular retinal diseases such as age-related macular degeneration or diabetic retinopathy. Current management of these conditions require regular and frequent intravitreal injections to prevent disease recurrence once the effect of the injected drug wears off. This has led to a pressing clinical need of developing sustained release formulations or therapies with longer duration. A major drawback in developing such therapies is that the currently available animal models show spontaneous regression of v...
Source: Experimental Eye Research - May 28, 2018 Category: Opthalmology Authors: Li Y, Busoy JM, Zaman BAA, Woon QTS, Tan GSW, Amutha Barathi V, Cheung N, Wei JJ, Hunziker W, Hong W, Wong TY, Cheung CMG Tags: Exp Eye Res Source Type: research

Assessing the role of ranibizumab in improving the outcome of glaucoma filtering surgery and neovascular glaucoma
Volume 18, Issue 6, June 2018, Page 719-724 . (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - May 25, 2018 Category: Drugs & Pharmacology Authors: Andreas Katsanos Kostantina Gorgoli Dimitrios G. Mikropoulos Esther Arranz-Marquez Georgios P. Athanasopoulos Miguel A. Teus Anastasios G.P. Konstas Source Type: research

Real study: Re-treatment evaluated on visual acuity for Lucentis ® in neovascular AMD.
CONCLUSION: This initial VA-guided regimen with ranibizumab might prevent the slight decrease in VA observed during the first year of PRN studies. PMID: 29779934 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - May 23, 2018 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Subfoveal Choroidal Thickness as a Potential Predictor of Clinical Response to Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration
Neovascular age-related macular degeneration (nAMD) is one of the leading causes of blindness in individuals older than 50 years of age in industrialized nations.1 The current gold standard for treatment involves intravitreal injections (IVIs) of drugs like aflibercept (Eylea; Regeneron, Tarrytown, NY), bevacizumab (Avastin; Genentech, South San Francisco, CA), and ranibizumab (Lucentis; Genentech, South San Francisco, CA), which primarily target the vascular endothelial growth factor A (VEGF-A).2 However, optimal treatment necessitates continual hospital review and repeated IVIs, which is (Source: Ophthalmic Surgery, Lase...
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - May 21, 2018 Category: Opthalmology Authors: Mahdy Ranjbar, MD Source Type: research

Long-Term Results of Combination Treatment with Single-Dose Ranibizumab plus Photodynamic Therapy for Retinal Angiomatous Proliferation
Conclusions: Single-dose modified anti-VEGF treatment in combination with PDT may provide long-term regression at the initial stages of RAP.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - May 16, 2018 Category: Opthalmology Source Type: research

Development and validation of a novel semi-homogenous clinical assay for quantitation of Ranibizumab in human serum.
In this report, we describe the development of a novel method that utilizes a high-affinity murine monoclonal anti-ranibizumab-VEGF-complexes antibody (MARA) reagent to measure ranibizumab in human serum. The assay format utilizes a semi-homogeneous solution phase step using a monoclonal antibody (the MARA) that binds specifically to the ranibizumab-VEGF complex, but not to either alone. This unique reagent exhibited low non-specific binding and high selectivity, increasing signal-to-noise readouts and maximizing assay sensitivity. The resulting MARA enzyme-linked immunosorbent assay (ELISA) has a lower limit of quantifica...
Source: Journal of Immunological Methods - May 14, 2018 Category: Allergy & Immunology Authors: Lowe J, Wakshull E, Shek T, Chuntharapai A, Elliott R, Rusit J, Maia M Tags: J Immunol Methods Source Type: research

Topographic Correspondence of Macular Atrophy with Choroidal Neovascularization in Ranibizumab Treated Eyes of the TREX-AMD Trial
To quantify the extent of topographic correspondence between baseline (BSL) CNV and macular atrophy (MA) at follow-up in eyes with NVAMD. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - May 12, 2018 Category: Opthalmology Authors: Nizar Saleh Abdelfattah, Amirhossein Hariri, Mayss Al-Sheikh, Sean Pitetta, Adel Ebraheem, Charles C. Wykoff, SriniVas R. Sadda, TREX-AMD Study Group Tags: Original Articles Source Type: research

Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial
To quantify the extent of topographic correspondence between baseline (BSL) choroidal neovascularization (CNV) and macular atrophy (MA) at follow-up in eyes with neovascular age-related macular degeneration (NVAMD). (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - May 12, 2018 Category: Opthalmology Authors: Nizar Saleh Abdelfattah, Amir H. Hariri, Mayss Al-Sheikh, Sean Pitetta, Adel Ebraheem, Charles C. Wykoff, SriniVas R. Sadda, TREX-AMD Study Group Tags: Original article Source Type: research

Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis
Age-related macular degeneration (AMD) is one of the prevailing causes of serious vision loss, mostly in people older than 55 years old in Western countries [1,2]. Characterized by choroidal neovascularization (CNV) [3], wet AMD covers about 20% of AMD patients, but it is responsible for almost 80%-90% severe vision loss [4 –8]. The intractability of wet AMD, however, lies in its relationships with age, metabolic changes in the retinal pigment epithelium, oxidative damage, especially light injury, inflammatory and immune disorders, genetic factors and so forth [4], confirming that AMD is an irreversible, chronic, deg...
Source: Photodiagnosis and Photodynamic Therapy - May 9, 2018 Category: Laser Surgery Authors: Yongxian Su, Jiawei Wu, Yu Gu Source Type: research

Influence of the Vitreoretinal Interface on the Treatment with Anti-VEGF for Exudative Age-Related Macular Degeneration
Conclusion: The negative impact of absence of PVD is regimen dependent, with monthly dosing providing similar outcomes to PVD patients. In the absence of PVD (group ON), PRN should be avoided, and Tamp;E might be an alternative.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - May 7, 2018 Category: Opthalmology Source Type: research

Direct Photocoagulation Guided by Merged Retinal Images for the Treatment of Focal Diabetic Macular Edema.
Conclusion: MIG-PC contributed to the improvement in BCVA and reduction in RT, number of laser shots required, and retreatment rates. Based on our data, MIG-PC can be recommended for the treatment of focal DME. This trial is registered with ID UMIN000030390. PMID: 29721014 [PubMed] (Source: International Journal of Endocrinology)
Source: International Journal of Endocrinology - May 4, 2018 Category: Endocrinology Tags: Int J Endocrinol Source Type: research

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age.
Authors: Chen YC, Chen SN, Yang BC, Lee KH, Chuang CC, Cheng CY Abstract Purpose: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) versus bevacizumab (IVB), at a corrected age of 3 years. Methods: A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for type 1 ROP, from April 2011 to April 2014. Results: A total of 62 eyes (33 patients) with type 1 ROP were evaluated (26 eyes in 13 IVR patients and 36 eyes in 20 IVB pa...
Source: Journal of Ophthalmology - May 2, 2018 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Extensive Submacular Hemorrhage After Trabeculectomy With Mitomycin C
Conclusions: To our knowledge, this is the first report of an extensive submacular hemorrhage after trabeculectomy with mitomycin C in a patient with an occult CNVM. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - May 1, 2018 Category: Opthalmology Tags: Online Articles: Case Report/Small Case Series Source Type: research

Error in Abstract and Tables
This article was corrected online. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - May 1, 2018 Category: Opthalmology Source Type: research

Cytomegalovirus retinitis, in a diabetic immunocompetent patient, after intravitreal ranibizumab injection.
Abstract We here report a case of cytomegalovirus retinitis in a diabetic patient that occurred after intravitreal ranibizumab injection. A 75-year-old woman was treated with intravitreal ranibizumab injections for diabetic macular edema. During this period, a retinitis occurred in her left eye along with increased IgG and later IgM cytomegalovirus antibody titers. Ocular and intravenous ganciclovir was administered. Cytomegalovirus retinitis subsided post treatment with residual areas of retinal atrophy. Ophthalmologists should be aware of the incidence of cytomegalovirus retinitis, in diabetic patients, after ra...
Source: European Journal of Ophthalmology - May 1, 2018 Category: Opthalmology Authors: Zafeiropoulos P, Tamboura P, Dimou M, Cristodoulou E, Stefaniotou M Tags: Eur J Ophthalmol Source Type: research

Intravitreal dexamethasone implantation in patients with different morphological diabetic macular edema having insufficient response to ranibizumab
Conclusion: Treatment algorithms should differ according to the morphology of diabetic macular edema; however, more data is needed to give specific recommendations. (Source: RETINA)
Source: RETINA - April 28, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained
Purpose: To assess whether visual benefits exist in switching to aflibercept in patients who have been chronically treated with ranibizumab for neovascular age-related macular degeneration. Methods: A multicenter, national, electronic medical record database study was performed. Patients undergoing six continuous monthly ranibizumab injections and then switched to continuous aflibercept were matched to those on continuous ranibizumab therapy. Matching was performed in a 2:1 ratio and based on visual acuity 6 months before and at the time of the switch, and the number of previous ranibizumab injections. Results: Pat...
Source: RETINA - April 28, 2018 Category: Opthalmology Tags: Original Study Source Type: research

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)
Acta Ophthalmologica, EarlyView. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - April 26, 2018 Category: Opthalmology Authors: Jana Stefanickova , Jose Cunha ‐Vaz , Michael Ulbig , Ian Pearce , Alvaro Fernández‐Vega Sanz , Panagiotis Theodossiadis , Laurent Kodjikian , Alexander Izmailov , Dominic Muston , Zdravko Vassilev , Benedicte Lamotte , Claudia Source Type: research

Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration.
This article aims to discuss the baseline factors associated with VA outcome such as age, initial VA, lesion types, disease duration, optical coherence tomography (OCT) features, fundus autofluorescence findings, and the presence of particular genotype risk alleles in patients with wAMD. Recommendations are provided regarding when to consider discontinuation of therapy because of either success or futility. Understanding the predictive factors associated with VA outcome and treatment frequency response to anti-VEGF therapy may help retina specialists to manage patients' expectations and guide treatment decisions from the b...
Source: Biomed Res - April 24, 2018 Category: Research Authors: Zhang X, Lai TYY Tags: Biomed Res Int Source Type: research

Clinical Efficacy and Safety of Current Interventions for Choroidal Neovascularization Associated with Rare Diseases: A Systematic Literature Review
AbstractIntroductionThe aim of this systematic literature review was to evaluate the efficacy and safety of interventions for the treatment of choroidal neovascularization (CNV) secondary to etiologies other than age-related macular degeneration and pathologic myopia.MethodsRelevant randomized controlled trials (RCTs) and prospective observational studies were identified by searching MEDLINE, MEDLINE In-Process, EMBASE, and CENTRAL.ResultsThe search identified 5 RCTs; no relevant observational studies were identified. The studies differed in terms of underlying cause of CNV, patient numbers (n = 9–178),...
Source: Advances in Therapy - April 23, 2018 Category: Drugs & Pharmacology Source Type: research

A Simple Vista en Este N úmero
Atchison y otros (p. 676) se propusieron identificar los efectos sostenidos de las inyecciones de antifactor de crecimiento endotelial vascular (VEGF) en la presi ón intraocular (IOP). Analizaron 23.873 pacientes del Registro AAO IRIS que recibieron una inyección intravítrea de aflibercept, bevacizumab o ranibizumab en el ojo derecho entre el 1 de enero de 2013 y el 31 de diciembre de 2015, utilizando los ojos contralaterales no tratados como comparación. Los pacientes mostraron una reducción estadísticamente significativa de la IOP con una media de 0,9 mmHg en los ojos tratados co...
Source: Ophthalmology - April 19, 2018 Category: Opthalmology Authors: Sandeep Ravindran Tags: This issue at a glance Source Type: research

This Issue at a Glance
Atchison et  al (p. 676) set out to identify the sustained effects of anti-vascular endothelial growth factor (VEGF) drug injections on intraocular pressure (IOP). They analyzed 23 873 patients from the AAO IRIS Registry who received an intravitreous injection with aflibercept, bevacizumab, or ranibizumab in their right eyes between January 1, 2013 and December 31, 2015, and they used fellow, untreated eyes for comparison. Patients showed a statistically significant decrease in IOP, with a mean of 0.9 mmHg in treated eyes compared with an average decrease of 0.2 mmHg in fellow, untreated eyes. (Source: Ophthalmology)
Source: Ophthalmology - April 19, 2018 Category: Opthalmology Authors: Sandeep Ravindran Tags: This issue at a glance Source Type: research

Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries
Diabetic retinopathy (DR) is the leading cause of blindness in individuals aged between 20 years and 74 years in the United States.1 Among those with DR, the number one cause of visual impairment is diabetic macular edema (DME).2 The advent of anti-vascular endothelial growth factor (VEGF) agents for the treatment of DME has greatly improved clinical outcomes in patients compared to laser therapy.3 However, the annual costs of anti-VEGF therapy exceeded $2.3 billion among the fee-for-service (FFS) Medicare population in 2008.4 Medicare reimbursements were $50 per bevacizumab (Avastin; (Source: Ophthalmic Surgery, Lasers an...
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - April 19, 2018 Category: Opthalmology Authors: Connie M. Wu, MD Source Type: research

Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial
Retinal vein occlusion (RVO) is a major cause of vision loss and typically results from thrombosis of venous outflow.1 This blockage can lead to retinal nonperfusion (RNP), physiologic ischemia, and release of angiogenic factors including vascular endothelial growth factor-A (VEGF-A).The advent of VEGF antagonists such as ranibizumab (Lucentis; Genentech, South San Francisco, CA), aflibercept (Eylea; Regeneron, Tarrytown, NY), and bevacizumab (Avastin; Genentech, South San Francisco, CA) has revolutionized the treatment and management of RVO, with multiple clinical trials demonstrating their (Source: Ophthalmic Surgery, La...
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - April 19, 2018 Category: Opthalmology Authors: William C. Ou, BS Source Type: research

Rethinking Management Strategies for Proliferative Diabetic Retinopathy
Seenu M. HariprasadPractical Retina Co-EditorFor this Practical Retina column, Peter H. Tang, MD, PhD, and Diana V. Do, MD, were asked to comment on the evolving paradigm for treating diabetic retinopathy (DR).Frequent discussion takes place regarding the current management of DR (especially proliferative diabetic retinopathy [PDR]) given the recent approval of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of DR without diabetic macular edema (DME). For instance, given the availability of ranibizumab (Lucentis; Genentech, South San Francisco, CA) to treat PDR, is (Source: Ophthalmic Surgery, Lase...
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - April 19, 2018 Category: Opthalmology Authors: Peter H. Tang, MD, PhD Source Type: research

Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
CONCLUSIONS: Combination of intravitreal anti-VEGF plus intravitreal steroids does not appear to offer additional visual benefit compared with monotherapy for DMO; at present the evidence for this is of low-certainty. There was an increased rate of cataract development and raised intraocular pressure in eyes treated with anti-VEGF plus steroid versus anti-VEGF alone. Patients were exposed to potential side effects of both these agents without reported additional benefit. The majority of the evidence comes from studies of bevacizumab and triamcinolone used as primary therapy for DMO. There is limited evidence from studies u...
Source: Cochrane Database of Systematic Reviews - April 18, 2018 Category: General Medicine Authors: Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser-Bell S Tags: Cochrane Database Syst Rev Source Type: research

The real life data of ranibizumab use among the diabetic macular edema patients in Turkey: documenting the improvement with clinical optimization during three consecutive years
Conclusions It is effortful to obey the strict follow-up criteria of prospective studies in DME patients on a PRN regimen. However, optimizing the clinical processes of patient management may lead to improved clinical outcomes in real life. (Source: Saudi Journal of Ophthalmology)
Source: Saudi Journal of Ophthalmology - April 14, 2018 Category: Opthalmology Source Type: research

[Long-term effects of anti-VEGF therapy for retinopathy of prematurity].
CONCLUSION: Long-term effects of anti-VEGF therapy in ROP differ significantly from alternative treatment options such as laser coagulation. These differences are of relevance for the choice of treatment modality and the follow-up regimen of treated children. PMID: 29654389 [PubMed - as supplied by publisher] (Source: Der Ophthalmologe)
Source: Der Ophthalmologe - April 13, 2018 Category: Opthalmology Authors: Krohne TU, Müller A, Larsen PP, Holz FG Tags: Ophthalmologe Source Type: research

Genetic Background of a Recurrent Unusual Combined Form of Retinal Vein Occlusion: A Case Report
The authors report a rare case of nonischemic branch retinal vein occlusion and nonischemic hemiretinal vein occlusion in a patient with impaired fibrinolysis. A 61-year-old woman presented to the Department of Ophthalmology, Clinical Hospital Center Split, Croatia, with acute blurring of vision in the right eye (RE) due to branch retinal vein occlusion. Ophthalmologic evaluation revealed a best corrected visual acuity (BCVA) of 0.02 in the RE and of 1.0 in the left eye. Ophthalmoscopy and fluorescein angiography of the RE demonstrated signs of nonischemic branch retinal vein occlusion. She was otherwise healthy and had no...
Source: Case Reports in Ophthalmology - April 12, 2018 Category: Opthalmology Source Type: research

Estimating Medicare and patient savings from the use of bevacizumab for the treatment of exudative age-related macular degeneration
The Medicare cost savings from the use of bevacizumab in the United States for the treatment of exudative age-related macular degeneration (AMD) were estimated by replacing the use of bevacizumab with ranibizumab and aflibercept. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - April 12, 2018 Category: Opthalmology Authors: Philip J. Rosenfeld, Matthew A. Windsor, William J. Feuer, Sissi J.J. Sun, Kevin D. Frick, Eric A. Swanson, David Huang Tags: Original Articles Source Type: research

[Treated cases of retinopathy of prematurity in Germany : 5-year data from the Retina.net ROP registry].
CONCLUSION: The data in this analysis represent about 10-15% of treated infants in Germany. The results provide evidence for an increasing use of anti-VEGF agents for ROP. The data reflect a selection bias for anti-VEGF treatment in eyes with a more aggressive disease. This needs to be considered when interpreting data such as disease recurrence rates. The risk for late recurrences after anti-VEGF treatment is of particular clinical significance. PMID: 29637302 [PubMed - as supplied by publisher] (Source: Der Ophthalmologe)
Source: Der Ophthalmologe - April 10, 2018 Category: Opthalmology Authors: Walz JM, Bemme S, Reichl S, Akman S, Breuß H, Süsskind D, Glitz B, Müller VC, Wagenfeld L, Gabel-Pfisterer A, Aisenbrey S, Engelmann K, Koutsonas A, Krohne TU, Stahl A, Retina.net ROP-Register-Studiengruppe Tags: Ophthalmologe Source Type: research

Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti
Publication date: Available online 6 April 2018 Source:Journal of American Association for Pediatric Ophthalmology and Strabismus Author(s): Yingqin Ni, Xin Huang, Lu Ruan, Kang Xue, Jia Yu, Jie Peng, Peiquan Zhao (Source: Journal of American Association for Pediatric Ophthalmology and Strabismus)
Source: Journal of American Association for Pediatric Ophthalmology and Strabismus - April 7, 2018 Category: Opthalmology Source Type: research

Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti
(Source: Journal of AAPOS)
Source: Journal of AAPOS - April 6, 2018 Category: Opthalmology Authors: Yingqin Ni, Xin Huang, Lu Ruan, Kang Xue, Jia Yu, Jie Peng, Peiquan Zhao Tags: Short Report Source Type: research

Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network
Purpose of review To present some recent clinically relevant results from Diabetic Retinopathy Clinical Research (DRCR) Network trials that may guide management of diabetic macular edema (DME) or proliferative diabetic retinopathy (PDR). Recent findings Among eyes with DME and visual acuity 20/50 or worse, aflibercept, on average, had greater improvement in visual acuity over 2 years compared with bevacizumab or ranibizumab. Aflibercept is associated with higher rates of improvements in diabetic retinopathy severity among eyes with PDR and vision-impairing DME at baseline compared with bevacizumab or ranibizumab. Amon...
Source: Current Opinion in Ophthalmology - April 5, 2018 Category: Opthalmology Tags: RETINAL, VITREOUS AND MACULAR DISORDERS: Edited by Brandon G. Busbee and John W. Kitchens Source Type: research

Influence of Serous Retinal Detachment on the Outcome of Ranibizumab Treatment in Diabetic Macular Edema.
CONCLUSIONS: The presence of SRD resulted in a less favorable visual acuity (VA) outcome with IVR. Disruption of the ellipsoid zone and abnormality of the foveal avascular zone at the baseline examination were correlated with a lower VA. Both of the pathologies occurred more frequently in the SRD group. PMID: 29619858 [PubMed - as supplied by publisher] (Source: Cutaneous and Ocular Toxicology)
Source: Cutaneous and Ocular Toxicology - April 5, 2018 Category: Toxicology Authors: Ercalik NY, Imamoglu S, Turkseven Kumral E, Yenerel NM, Bardak H, Bardak Y Tags: Cutan Ocul Toxicol Source Type: research

Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis
Conclusion: The regimen including mitomycin, interferon, and trabeculectomy was the most likely to improve the treatment success rate in NVG patients. The application of glaucoma valve and bevacizumab were more beneficial for improving patient treatment success rate as a surgery and as an agent, respectively. (Source: Medicine)
Source: Medicine - April 1, 2018 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Unilateral macular choroidal neovascularization—a rare manifestation in acute myelocytic leukemia: Case report
Rationale: Characteristic signs of leukemic retinopathy include bilateral intra-retinal hemorrhage, white-centred hemorrhage, macular hemorrhage and cotton-wool spots. Capillary closure, retinal microaneurysms and neovascularization following massive fundus hemorrhage could be involved in few of the above instances. However, single choroidal neovascularization (CNV) in macular has not been observed in acute myelocytic leukemia (AML). Patient concerns: A 22-year-old woman presented with a 7-day history of vision decline in the right eye (OD). The patient was diagnosed as M3 AML one month earlier. Chemotherapy was immed...
Source: Medicine - April 1, 2018 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Abstract OBJECTIVE: To evaluate the effect of anti-vascular endothelial growth factor (VEGF) on juxtafoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MFC) and wet age-related macular degeneration (AMD). METHODS: In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups: 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal (IVT) injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization. RESULTS: S...
Source: J Zhejiang Univ Sci ... - April 1, 2018 Category: Science Authors: Feng L, Hu JH, Chen J, Xie X Tags: J Zhejiang Univ Sci B Source Type: research

Aqueous Humor Cytokine Levels and Ranibizumab in Diabetic Macular Edema
This cohort study investigates aqueous humor cytokine level changes in response to intravitreal ranibizumab therapy for the management of diabetic macular edema. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - April 1, 2018 Category: Opthalmology Source Type: research

Association of Changes in Macular Perfusion With Ranibizumab Treatment
This post hoc analysis of data from a randomized clinical trial evaluates the association of repeated ranibizumab injections on macular perfusion in patients with diabetic macular edema as compared with laser monotherapy or ranibizumab and laser combination therapy. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - April 1, 2018 Category: Opthalmology Source Type: research

A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion.
CONCLUSION: Dexamethasone and ranibizumab improved best-corrected visual acuity and anatomical outcomes; however, dexamethasone did not show non-inferiority to ranibizumab in this under-powered study. Dexamethasone was associated with an increased risk of intraocular pressure elevation and cataract progression, but a lower injection burden, compared to ranibizumab. PMID: 29631435 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - April 1, 2018 Category: Opthalmology Authors: Bandello F, Augustin A, Tufail A, Leaback R Tags: Eur J Ophthalmol Source Type: research

An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration
AbstractObjectiveTo evaluate the effect of anti-vascular endothelial growth factor (VEGF) on juxtafoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MFC) and wet age-related macular degeneration (AMD). Methods: In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups: 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal (IVT) injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization.ResultsSignificant improvements w...
Source: Journal of Zhejiang University. Science. B. - April 1, 2018 Category: Universities & Medical Training Source Type: research

Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion.
MH Abstract PURPOSE: To compare the effects of intravitreal ranibizumab injection and yellow (577 nm) subthreshold micropulse laser treatment in patients with macular edema following non-ischemic branch retinal vein occlusion. METHODS: The medical records of 51 patients who underwent intravitreal ranibizumab (0.5 mg) injection or subthreshold micropulse laser for the treatment of macular edema due to branch retinal vein occlusion were retrospectively reviewed. Subthreshold micropulse laser was administered with a 10% duty cycle, 100 μm spot diameter, 200 ms exposure time. The patients received an injectio...
Source: European Journal of Ophthalmology - April 1, 2018 Category: Opthalmology Authors: Buyru Özkurt Y, Akkaya S, Aksoy S, Şimşek MH Tags: Eur J Ophthalmol Source Type: research